Prelude Therapeutics(PRLD)
$3.76+0.00 (+4.44%)
PRLD
Prelude Therapeutics financials statements
$3.76
At close:+0.00 (+4.44%)
Want to see PRLD full AI Analyst Report?
Prelude Therapeutics (PRLD) Ratios
196 Followers
Prelude Therapeutics Ratios
PRLD's free cash flow for Q2 2026 was $-15.57M. For the 2026 fiscal year, PRLD's free cash flow was increased by $0.00 and operating cash flow was $-15.57M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.99 | 5.30 | 10.79 | 9.42 | 15.37 |
| Quick Ratio | 1.99 | 5.30 | 10.79 | 9.42 | 15.37 |
| Cash Ratio | 0.67 | 0.49 | 1.16 | 1.41 | 1.66 |
| Solvency Ratio | -1.35 | -2.85 | -2.97 | -4.55 | -5.77 |
| Operating Cash Flow Ratio | -1.06 | -4.01 | -4.90 | -3.86 | -4.35 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 33.01M | $ 91.84M | $ 195.01M | $ 179.32M | $ 275.91M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.13 | 0.10 | 0.06 | 0.01 | 0.01 |
| Debt-to-Equity Ratio | 0.26 | 0.14 | 0.07 | 0.01 | 0.01 |
| Debt-to-Capital Ratio | 0.21 | 0.12 | 0.07 | 0.01 | 0.01 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 2.06 | 1.34 | 1.17 | 1.13 | 1.07 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.23 | 0.24 | 0.28 | 0.04 | 0.04 |
| Net Debt to EBITDA | 0.18 | -0.04 | 0.06 | 0.24 | 0.27 |
| Profitability Margins | |||||
| Gross Profit Margin | 85.91% | 100.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | -819.59% | -1816.76% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | -805.49% | -1791.44% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | -861.33% | -1995.91% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | -819.59% | -1816.76% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | -819.59% | -1816.76% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | -819.59% | -1816.76% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 95.15% | 91.02% | 92.10% | 93.44% | 98.21% |
| Return on Assets (ROA) | -70.41% | -72.46% | -43.88% | -52.35% | -36.61% |
| Return on Equity (ROE) | -144.96% | -96.74% | -51.39% | -59.07% | -39.07% |
| Return on Capital Employed (ROCE) | -118.39% | -93.22% | -51.70% | -62.14% | -39.78% |
| Return on Invested Capital (ROIC) | -114.83% | -91.57% | -51.41% | -61.58% | -39.54% |
| Return on Tangible Assets | -70.41% | -72.46% | -43.88% | -52.35% | -36.61% |
| Earnings Yield | -44.58% | -132.10% | -47.27% | -40.35% | -18.85% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.43 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.38 | 0.20 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.09 | 0.04 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.15 | 0.04 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -849.68 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 849.68 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.73 | -1.36 | -1.77 | -1.77 | -1.75 |
| Free Cash Flow Per Share | -0.73 | -1.37 | -1.83 | -1.83 | -1.80 |
| Dividend Paid and CapEx Coverage Ratio | -840.33 | -134.67 | -30.48 | -27.73 | -35.96 |
| Capital Expenditure Coverage Ratio | -840.33 | -134.67 | -30.48 | -27.73 | -35.96 |
| Operating Cash Flow Coverage Ratio | -3.16 | -5.71 | -6.34 | -45.70 | -48.01 |
| Operating Cash Flow to Sales Ratio | -4.64 | -14.70 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -25.26% | -107.66% | -42.90% | -30.32% | -14.49% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -2.25 | -0.76 | -2.12 | -2.48 | -5.31 |
| Price-to-Sales (P/S) Ratio | 18.38 | 13.75 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 3.25 | 0.73 | 1.09 | 1.46 | 2.07 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -3.96 | -0.93 | -2.33 | -3.30 | -6.90 |
| Price-to-Operating Cash Flow Ratio | -3.96 | -0.94 | -2.41 | -3.42 | -7.09 |
| Price-to-Earnings Growth (PEG) Ratio | 0.10 | 0.04 | 0.19 | 0.96 | -0.07 |
| Enterprise Value Multiple | -1.48 | -0.60 | -1.36 | -1.46 | -3.54 |
| Enterprise Value | 144.40M | 75.38M | 178.52M | 178.75M | 399.75M |
| EV to EBITDA | -1.48 | -0.60 | -1.36 | -1.46 | -3.54 |
| EV to Sales | 11.89 | 10.77 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -2.56 | -0.73 | -1.61 | -2.06 | -4.66 |
| EV to Operating Cash Flow | -2.56 | -0.73 | -1.67 | -2.13 | -4.79 |
| Tangible Book Value Per Share | 0.89 | 1.73 | 3.93 | 4.13 | 6.01 |
| Shareholders’ Equity Per Share | 0.89 | 1.73 | 3.93 | 4.13 | 6.01 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.16 | 0.09 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -1.29 | -1.68 | -2.02 | -2.44 | -2.35 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 0.92 | 0.93 | 0.98 |
| Research & Development to Revenue | 7.77 | 16.86 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 1.85 | 4.10 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.98 | 3.05 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.57 | 0.81 | 0.88 | 0.73 | 0.75 |
Currency in USD
